Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

8月8日，两家AI制药龙头公司Recursion和Exscientia宣布已达成最终协议合并。Recursion是英伟达力挺的AI制药公司，致力于构建大型生物分子生成式AI模型，以实现药物发现的工业化；Exscientia则是更“传统意义”上的AI制药公司，利用高精度数据进行药物筛选、设计与开发。

The stock looks cheap, but appearances can be deceiving.

7×24小时Recursion Pharmaceuticals（RXRX）股票快讯，包括最近Recursion Pharmaceuticals Inc（RXRX）股票市场行情资讯和影响股票涨跌的国际与经济时事。今日Recursion Pharmaceuticals股票最新消息与行情走势尽在掌握。 递归制药公司（Recursion Pharmaceuticals Inc.，股票代码：RXRX）股价在 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June ...